Clinical Trial · NCT02286531

Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma

Overview

Determine the overall discriminatory ability of FET PET in the diagnosis of glioma grade II (referring to the current diagnostic gold standard represented by the histopathology exam of a tumor sample).

Sponsor

University Hospital Tuebingen

Phase

N/A

Contacts

Pierre Payoux, MD PHD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02286531

Drug / Compound

O-(2-[18F]-fluoroethyl)-L-tyrosine

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Patients over 18 years
Histological examination scheduled within one month with FET PET by resection (complete or partial) or by biopsy
Realization of a brain MRI in preoperative condition of neuronavigation (MRI sequences including axial T2, Flair, T1, T1 with gadolinium) in a within 1 month with FET PET.
Diagnosis of glioma grade II referred on clinical and MRI morphologic
No against-indication for PET
No against-indications to MRI

Exclusion

Patient under guardianship
Weight greater than 120 Kg
No coverage by social security
Grade II glioma who have received specific treatment with radiotherapy and or chemotherapy.
against-indication to PET
against- indication gadolinium
Possible side effects to MRI (magnetic foreign bodies, pacemaker, congestive severe renal).)
Pregnant or breastfeeding women.